GRIFOLS, S.A. The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 04/07/2019 15:15 GRIFOLS, S.A. R&D: new licenses, patents and registered trademarks The U.S. Food and Drug Administration has approved Grifols´ new 20% subcutaneous immunoglobulin product, Xembify®, which is used to treat primary immunodeficiencies. Register number: 279882